摘要
目的 探讨宫颈环形电切术(LEEP)联合重组人干扰素α-2b栓治疗宫颈上皮内瘤变(CIN)的临床效果。方法 选择经液基细胞学检查(TCT)、宫颈活检病理检查明确诊断为CINⅠ~Ⅲ级患者82例,均于LEEP治疗前应用导流杂交法检测21种亚型人乳头瘤病毒(HPV DNA),均行LEEP治疗,观察组(41例)为LEEP术后加用重组人干扰素α-2b栓治疗3个疗程患者,分别于治疗后6、12个月行TCT及HPV DNA检测以判断两组的疗效。结果 观察组术后6个月治愈率90.2%,术后12个月治愈率100.0%;对照组术后6个月治愈率43.9%,术后12个月治愈率61.0%;两组6、12个月治愈率差异均有统计学意义(χ2=19.93、19.89,均P〈0.05)。结论 宫颈环形电切术联合重组人干扰素α-2b栓治疗CIN疗效优于单纯宫颈环形电切术,提高HPV清除率。
Objective To study the effect of combining loop electrosurgical excision procedure (LEEP) and recombinant human interferon α2b (rhIFNα-2b) suppository in treatment of cervical intraepithelial neoplasia (CIN).Methods Prospective,random and control study was conducted in 82 patients with CINI-CINIII.Before carrying out LEEP to these patients,all women were performed HPV DNA detection by the method of Hybri Max.Among these patients,41 patients were assigned to the studying group, in which the patients were given rhIFNα-2b suppository for three courses of treatment after LEEP.The other 41 patients who carried out LEEP simply were assigned to the control group.Liquid-based ThinPrep cytology test (TCT) and HPV DNA were examined in the sixth and twelfth month after treatment.Results In the studying group,the cure rate was 90.2% when LEEP ended six months, and the cure rate was 100.0% when LEEP ended twelve months.In the control group,the cure rate was 43.9% when LEEP ended six months, and the cure rate was 61.0% when LEEP ended twelve months.In the sixth and twelfth month after LEEP,the difference was significant when we compared the cure rate between the two groups(χ2=19.93,19.89,all P〈0.05).Conclusion The clinical effect of combining LEEP and rhIFNα-2b suppository is better than LEEP in treatment of CIN.The method can remove or destroy the cervical lesions effectively and inhibit HPV replication and spread of HPV infection.
出处
《中国基层医药》
CAS
2013年第11期1606-1608,共3页
Chinese Journal of Primary Medicine and Pharmacy
关键词
宫颈环形电切术
重组人干扰素Α-2B栓
宫颈上皮内瘤样变
人乳头瘤病毒
Loop electrosurgical excision procedure
Interferon alfa-2b suppository
Cervical intraepithelial neoplasia
Human papillomavirus